Welcome to our dedicated page for Caredx news (Ticker: CDNA), a resource for investors and traders seeking the latest updates and insights on Caredx stock.
CareDx Inc (CDNA) delivers innovative non-invasive diagnostics for transplant patient care through advanced genomics and bioinformatics. This news hub provides investors and healthcare professionals with essential updates on the company's developments in precision medicine.
Key resources include: Earnings reports detailing financial performance in transplant diagnostics, regulatory updates on FDA-cleared testing solutions, and strategic partnership announcements expanding into hematology oncology. Track clinical trial outcomes validating AlloSure® monitoring and discover operational milestones in digital health integration.
Our curated collection enables efficient tracking of CDNA's progress in reducing invasive biopsies through blood-based dd-cfDNA analysis. Stay informed about innovations in kidney, heart, and lung transplant surveillance technologies that are reshaping organ rejection management.
Bookmark this page for real-time updates on CareDx's evidence-based diagnostic solutions and their impact on transplant care standards. Verify analysis dates and consult official filings for complete context on all developments.
CareDx (Nasdaq: CDNA) announced the third SHORE manuscript published in the Journal of Heart and Lung Transplantation on November 24, 2025, reporting prognostic value for HeartCare® molecular testing in heart transplant recipients.
The study of 1,934 patients across 59 centers found that positive HeartCare results (both AlloMap and AlloSure Heart) at 2–6 months post‑transplant were linked to a nearly twofold higher one‑year cumulative incidence of graft dysfunction and cardiovascular death (15.5% vs. 8.5% or lower; p=0.009). A positive HeartCare result at any time (2 months–5 years) was associated with a threefold increase in 30‑day risk of those outcomes. Elevated molecular signals identified risk even when biopsies were normal, supporting HeartCare's independent prognostic role.
CareDx (Nasdaq: CDNA) will participate in two investor conferences in late 2025: a Fireside Chat at the Stephens Investment Conference in Nashville on Wednesday, November 19, 2025 at 8:00 AM CT, and a presentation at the Piper Sandler Healthcare Conference in New York on Wednesday, December 3, 2025 at 4:30 PM ET.
Live and archived webcasts of both presentations will be available in the Events and Presentations section of CareDx investor relations at investors.caredx.com.
CareDx (Nasdaq: CDNA) announced inducement equity awards on November 4, 2025 under its 2025 Inducement Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The company granted restricted stock units (RSUs) to 49 new employees totaling 113,250 shares and separately granted 88,180 RSUs to Dr. Jeffrey Teuteberg upon his appointment as Chief Medical Officer. The RSUs vest over four years: 25% on the first anniversary of each recipient’s vesting commencement date and thereafter 1/16th each quarter, subject to continued service.
CareDx (Nasdaq: CDNA) announced new kidney transplant molecular data and the launch of HistoMap Kidney, a tissue-based gene expression assay that complements pathology to characterize rejection phenotypes.
Key scientific presentations at ASN Kidney Week 2025 (Nov 6–8) included AlloView/AlloSure Plus performance for predicting antibody-mediated rejection, a 54-patient study finding donor kidney volume did not affect AlloSure levels or 1-year graft function, and results showing AlloSure plus blood gene expression profiling are usable for rejection screening from week 1 post-transplant. HistoMap Kidney will be available early 2026 via a clinical study.
CareDx (Nasdaq: CDNA) reported Q3 2025 revenue of $100.1M, up 21% year‑over‑year, driven by testing services revenue of $72.2M (+19%) and testing volume of ~50,300 samples (+13%). GAAP net income was $1.7M versus a GAAP loss of $10.6M in Q3 2024; adjusted EBITDA was $15.3M versus $6.9M a year earlier. Cash, cash equivalents and marketable securities totaled $194.2M as of September 30, 2025, net of a $25.6M share repurchase; no debt outstanding. The company raised full‑year 2025 revenue guidance to $372M–$376M and adjusted EBITDA guidance to $35M–$39M.
CareDx (Nasdaq: CDNA) announced the appointment of Jeffrey John Teuteberg, MD as Chief Medical Officer, effective October 1, 2025. Dr. Teuteberg brings more than two decades of clinical transplantation experience, including senior roles at Stanford and University of Pittsburgh Medical Center, board certification in Heart Failure/Cardiac Transplantation, and prior service as President of ISHLT.
He will lead CareDx’s global Medical Affairs, including Medical Directors, Medical Science Liaisons, and clinical research operations, and has served as principal investigator of the SHORE study on noninvasive rejection surveillance.
CareDx (Nasdaq: CDNA) published the second SHORE study in Journal of the American College of Cardiology: Heart Failure on October 23, 2025, reporting the largest prospective analysis of antibody-mediated rejection (AMR) in heart transplantation.
The study covered 2,240 patients across 59 U.S. centers, analysing 24,768 biopsies, 8,851 paired AlloSure Heart dd-cfDNA samples, and 136 AMR-positive biopsies paired with dd-cfDNA. AlloSure Heart ≥0.50% showed 92.8% specificity for AMR. Results supported context-dependent AlloSure thresholds to reduce unnecessary biopsies and showed AlloSure declines after presumed AMR treatment, indicating response monitoring utility.
CareDx (Nasdaq: CDNA) announced on October 22, 2025 the appointment of Suresh Gunasekaran to its Board of Directors.
Gunasekaran is president and CEO of UCSF Health, which the release notes has over $9 billion in annual revenue and 20,000 employees. He brings more than 20 years of executive leadership in healthcare administration and information technology and prior CEO and senior roles at University of Iowa Hospitals & Clinics, UT Southwestern, Healthlink/IBM, Gartner, and Vanderbilt Children’s Hospital.
CareDx highlighted Gunasekaran’s experience in clinical innovation and health system leadership and said his perspective will support the company’s efforts to advance diagnostic solutions for transplant patients.
CareDx (Nasdaq: CDNA) will report third quarter 2025 financial results after market close on Tuesday, November 4, 2025. The company will host a webcast and conference call the same day at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived webcast will be available on the Events & Presentations section of CareDx's Investor Relations website at investors.caredx.com. Telephone participants must register to receive a dial-in number and unique PIN.
CareDx (Nasdaq: CDNA) announced product launches and regulatory milestones at ASHI 2025 (Oct 6–10, 2025) highlighting new HLA diagnostics and European IVDR certification. Key items include the AlloSeq Tx11 launch with enhanced Class II coverage plus non‑HLA markers (ABO, CCR5, LIMS1, APOL1); a modernized SCORE 7 analysis app for QTYPE; a novel same‑day long‑read HLA assay offered via an Early Access Program; and an ABO genotyping qPCR assay that showed 100% concordance with established methods across three clinical sites. CareDx said its AlloSeq Tx and QTYPE products received IVDR certification in the EU, meeting the new regulatory standard ahead of the December 2027 deadline.
FAQ
What is the current stock price of Caredx (CDNA)?
What is the market cap of Caredx (CDNA)?
